Neurocognition and functional outcome in patients with psychotic, non-psychotic bipolar I disorder, and schizophrenia. A five-year follow-up

Abstract
Background: Bipolar disorder (BD) and schizophrenia (SZ) are characterized by neurocognitive and functional deficits with marked heterogeneity. It has been suggested that BD with a history of psychotic symptoms (BD-P) could constitute a phenotypically homogeneous subtype characterized by greater neurocognitive and functional impairments, or by a distinct trajectory of such deficits. The aim of this study was to compare the neurocognitive and functional course of euthymic BD-P, euthymic BD patients without a history of psychosis (BD-NP), stabilized patients with schizophrenia and healthy subjects, during a five-year follow-up. Methods: Neurocognitive and psychosocial function was examined in 100 euthymic patients with BD (50 BD-P, 50 BD-NP), 50 stabilized patients with schizophrenia (SZ), and 51 healthy controls (HC) at baseline (T1), and after a 5-year follow-up (T2). Results: The course of both neurocognitive performance and functional outcome of patients with SZ and BD (BD-P and BD-NP) is stable. The profile of neurocognitive impairment of patients with SZ or BD (BD-P and BD-NP), is similar, with only quantitative differences circumscribed to certain domains, such as working memory. The subgroup of patients with BD-NP does not show functional deterioration. Conclusions: We have not found evidence of progression in the neurocognitive or psychosocial impairment in any of the three groups of patients, although it cannot be dismissed the possibility of a subset of patients with a progressive course. Other longitudinal studies with larger samples and longer duration are necessary to confirm these findings. (c) 2018 Elsevier Masson SAS. All rights reserved.
Funding Information
  • Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS)
  • Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)
  • Madrid Regional Government (S2010/BMD-2422 AGES, B2017/BMD-3740 AGES CM 2-CM)
  • JanssenCilag
  • Lundbeck
  • Otsuka
  • Pfizer
  • Ferrer
  • Juste
  • Takeda
  • AB-Biotics
  • Allergan
  • Angelini
  • AstraZeneca
  • Bristol-Myers Squibb
  • Dainippon Sumitomo Pharma
  • Farmindustria
  • Ferrer
  • Forest Research Institute
  • Gedeon Richter
  • Glaxo-Smith-Kline
  • Janssen
  • Lundbeck
  • Otsuka
  • Pfizer
  • Roche
  • Sanofi-Aventis
  • Servier
  • Shire
  • Sunovion
  • Takeda
  • Brain and Behaviour Foundation
  • Spanish Ministry of Science and Innovation (CIBERSAM)
  • Seventh European Framework Programme (ENBREC)
  • Stanley Medical Research Institute